BioMarker Strategies, LLC today announced that the National Cancer Institute (NCI) has awarded the Company a Phase I Small Business Innovation Research (SBIR) grant for development of a pathway-based companion diagnostic test to identify patients with head and neck squamous cell carcinoma (HNSCC) who are most likely to respond to treatment with cetuximab. The grant will provide $299,000 in research support.
{iframe}http://www.businesswire.com/news/home/20171003006519/en/BioMarker-Strategies-Announces-Phase-National-Cancer-Institute{/iframe}